Sobi's Tryngolza wins EU approval for severe hypertriglyceridemia
IONS•The European Commission approved Tryngolza for adults with severe hypertriglyceridemia alongside diet and other lipid-lowering therapies. The approval expands its existing authorization for familial chylomicronemia syndrome.
1. Expanded EU authorization
The European Commission cleared Tryngolza (olezarsen) to treat adults with severe hypertriglyceridemia alongside diet and other lipid-lowering therapies. The expanded authorization makes it the EU’s first RNA-targeted treatment for this population.
2. Trial results and rights
Previously presented Phase 3 CORE and CORE2 results showed significant reductions in triglyceride levels and acute pancreatitis episodes versus placebo. Ionis developed Tryngolza, and Sobi holds exclusive commercialization rights outside the United States, excluding Canada and China.




